Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Achenbach

Showing results (51-60 of 108) with videos related to

Pageof 11
Sort By:
Clinica Chimica Acta; International Journal of Clinical Chemistry|August 30, 2016
3 Screen islet cell autoantibody ELISA: A sensitive and specific ELISA for the combined measurement of autoantibodies to GAD<sub>65</sub>, to IA-2 and to ZnT8Marie Amoroso, Peter Achenbach, Michael Powell, et al.
Diabetes, Obesity & Metabolism|April 22, 2026
Health Care Provider Perceptions of Screening for Early-Stage Type 1 Diabetes-A Survey StudyClaire Cherdron, Peter Achenbach, Kathrin Ackermann, et al.
BMC Medicine|June 20, 2024
First-in-human, double-blind, randomized phase 1b study of peptide immunotherapy IMCY-0098 in new-onset type 1 diabetes: an exploratory analysis of immune biomarkersJean Van Rampelbergh, Peter Achenbach, Richard David Leslie, et al.
Diabetologia|November 6, 2016
Peptide serum markers in islet autoantibody-positive childrenChristine von Toerne, Michael Laimighofer, Peter Achenbach, et al.
Diabetes Care|November 11, 2021
Islet Autoantibody Type-Specific Titer Thresholds Improve Stratification of Risk of Progression to Type 1 Diabetes in ChildrenKenney Ng, Harry Stavropoulos, Vibha Anand, et al.
Diabetes|May 15, 2015
Detection of Antibodies Directed to the N-Terminal Region of GAD Is Dependent on Assay Format and Contributes to Differences in the Specificity of GAD Autoantibody Assays for Type 1 DiabetesAlistair J K Williams, Vito Lampasona, Michael Schlosser, et al.
Diabetologia|October 4, 2022
Quantifying the utility of islet autoantibody levels in the prediction of type 1 diabetes in childrenKenney Ng, Vibha Anand, Harry Stavropoulos, et al.
Diabetes|September 16, 2022
Islet Autoantibody Levels Differentiate Progression Trajectories in Individuals With Presymptomatic Type 1 DiabetesBum Chul Kwon, Peter Achenbach, Vibha Anand, et al.
Diabetologia|October 4, 2022
Correction to: Progression likelihood score identifies substages of presymptomatic type 1 diabetes in childhood public health screeningAndreas Weiss, Jose Zapardiel-Gonzalo, Franziska Voss, et al.
Diabetologia|August 26, 2022
Progression likelihood score identifies substages of presymptomatic type 1 diabetes in childhood public health screeningAndreas Weiss, Jose Zapardiel-Gonzalo, Franziska Voss, et al.
Pageof 11

Showing results (51-60 of 108) with videos related to

Sort By:
Pageof 11
Clinica Chimica Acta; International Journal of Clinical Chemistry|August 30, 2016
3 Screen islet cell autoantibody ELISA: A sensitive and specific ELISA for the combined measurement of autoantibodies to GAD<sub>65</sub>, to IA-2 and to ZnT8Marie Amoroso, Peter Achenbach, Michael Powell, et al.
Diabetes, Obesity & Metabolism|April 22, 2026
Health Care Provider Perceptions of Screening for Early-Stage Type 1 Diabetes-A Survey StudyClaire Cherdron, Peter Achenbach, Kathrin Ackermann, et al.
BMC Medicine|June 20, 2024
First-in-human, double-blind, randomized phase 1b study of peptide immunotherapy IMCY-0098 in new-onset type 1 diabetes: an exploratory analysis of immune biomarkersJean Van Rampelbergh, Peter Achenbach, Richard David Leslie, et al.
Diabetologia|November 6, 2016
Peptide serum markers in islet autoantibody-positive childrenChristine von Toerne, Michael Laimighofer, Peter Achenbach, et al.
Diabetes Care|November 11, 2021
Islet Autoantibody Type-Specific Titer Thresholds Improve Stratification of Risk of Progression to Type 1 Diabetes in ChildrenKenney Ng, Harry Stavropoulos, Vibha Anand, et al.
Diabetes|May 15, 2015
Detection of Antibodies Directed to the N-Terminal Region of GAD Is Dependent on Assay Format and Contributes to Differences in the Specificity of GAD Autoantibody Assays for Type 1 DiabetesAlistair J K Williams, Vito Lampasona, Michael Schlosser, et al.
Diabetologia|October 4, 2022
Quantifying the utility of islet autoantibody levels in the prediction of type 1 diabetes in childrenKenney Ng, Vibha Anand, Harry Stavropoulos, et al.
Diabetes|September 16, 2022
Islet Autoantibody Levels Differentiate Progression Trajectories in Individuals With Presymptomatic Type 1 DiabetesBum Chul Kwon, Peter Achenbach, Vibha Anand, et al.
Diabetologia|October 4, 2022
Correction to: Progression likelihood score identifies substages of presymptomatic type 1 diabetes in childhood public health screeningAndreas Weiss, Jose Zapardiel-Gonzalo, Franziska Voss, et al.
Diabetologia|August 26, 2022
Progression likelihood score identifies substages of presymptomatic type 1 diabetes in childhood public health screeningAndreas Weiss, Jose Zapardiel-Gonzalo, Franziska Voss, et al.
Pageof 11